Developmental Clinical Studies:To determine the effectiveness of kisspeptin to induce oocyte maturation in IVF treatment

体外受精(IVF)治疗被广泛且成功地用于治疗不孕症，但可能会导致威胁生命的卵巢过度刺激综合征(OHSS)。轻度OHSS发生在大约1/3的体外受精周期，而中度或重度OHSS发生在多达1/10的体外受精周期。原因是在试管受精治疗中使用了一种药物，这种药物过于强烈地刺激了生殖激素的释放。Kispeptin是一种自然存在于男性和女性身上的激素，它刺激生殖激素的分泌，类似于正常月经周期的女性。在这项研究中，我们将发现Kispeptin在需要体外受精治疗的患者中有多有效。最终，我们研究的目的将是确定在试管受精治疗中使用Kispeptin是否可以预防患有不孕不育的女性OHSS的潜在生命威胁风险，这些女性在其他方面都很健康。

In vitro fertilisation (IVF) treatment is widely and successfully used to treat infertility, but can cause the life threatening condition called ovarian hyperstimulation syndrome (OHSS). Mild forms of OHSS occur in approximately 1/3rd of all IVF cycles, whilst moderate or severe OHSS occurs in up to 1/10th of IVF cycles. The cause is the use of a drug in IVF treatment which too powerfully stimulates the release of reproductive hormones. Kisspeptin is a hormone found naturally in men and women and it stimulates reproductive hormone secretion similarly to the stimulation which occurs in women with a normal menstrual cycle. In this study we will find out how effective kisspeptin is in patients requiring IVF treatment. Ultimately the aim of our research will be to determine if the use of kisspeptin in IVF treatment could prevent the potentially life threatening risk of OHSS in women with infertility who are otherwise healthy.